Biopharmaceuticals offer numerous advantages that are driving enhanced production on a worldwide basis. For instance, they have a stronger focus on target diseases and provide more effective and potent action. They also entail fewer side effects and have great potential to actually cure diseases rather than merely treat the symptoms. Moreover, biopharmaceuticals ? which are generally injected directly into the blood stream and are very fragile molecules ? degenerate very easily in the human digestive system. With the growing number of new diseases that can be treated with biopharmaceuticals, the demand for these drugs is on the increase, leading to increased manufacturing.

This Frost & Sullivan strategic analysis service provides global coverage of the manufacturing capabilities of biopharmaceuticals. It provides detailed quantification of the supply and demand for production capacities. It also examines the demand-supply balance and offers strategic recommendations to address the challenges arising from the inequalities in this balance.

Understanding the Demand-Supply Balance of Manufacturing Capacities Vital for Biopharmaceuticals Industry Progression

"The capacity gap - which is the difference between the supply and demand of manufacturing capacities - presents a fundamental challenge to the industry," observes the analyst of this research service. "Deficit of capacity is likely to significantly affect industry progression." Biopharmaceuticals developers need to understand the existing capacity gap in the market as well as evaluate their own financial positions. Based on this demand-supply situation, they can enter into long-term contracts with contract manufacturing organisations (CMOs) or invest in building manufacturing plants.

Frost & Sullivan estimates that the global manufacturing capacity ? Including that held by captive use and contract manufacturers ? Will grow from 2.27 million litres in 2004 to 3.69 million litres in 2011 at a compound annual growth rate (CAGR) of 7.2 per cent. The global demand for manufacturing capacity, on the other hand, stands at 1.37 million litres in 2004 and is likely to increase to 3.13 million litres in 2011. Currently, there is overcapacity in the industry with capacity utilisation pegged at around 60 per cent. This is likely to increase to 70 per cent by the end of 2006 and 80 per cent in 2008, after which demand will continue to rise due to key drug approvals.

Drying Product Pipeline and Absence of Intellectual Property Laws are Causes for Concern

"Resource and product portfolio management is proving to be a key challenge to the biopharmaceuticals industry," says the analyst. "There are growing concerns about the drug pipeline drying up in the pharmaceuticals industry and this extends to biopharmaceuticals as well." Additionally, the lack of internationally accredited intellectual property laws or patent models prevents companies from innovating and causes them to limit application to certain countries only.

Companies will have to collaborate with academics to clarify the patents required for a particular licence. Subsequently, keeping a track of developments in the areas where they have filed for patents is essential. Only then will companies be able to realise the full potential of this industry.

Frost & Sullivan Growth Partnership Service

Based on extensive and in-depth research, real-world consulting work, and new theories tested in hundreds of companies across many industries, Frost & Sullivan has evolved its Growth Partnership Services (GPS) programme that provides established and emerging firms with powerful growth visions. Moving beyond token mission statements, GPS provides an actionable vision to growth consulting partners by illustrating how key intelligence and strategic research based on defined goals can guide day-to-day behaviour and overall company direction. The foundation of Frost & Sullivans GPS includes:

Assisting companies to reach their full potential in the core business
Providing growth strategies to help companies expand into related businesses
Preemptively redefining the core business during market turbulence
Applying the Frost & Sullivan framework to identify and address common mistakes resulting from misaligned corporate strategies
Recommending growth management strategies through continuous partnership

To maximise the potential for growth within a firms internal and external environment, Frost & Sullivan consultants can facilitate the creation of strategic programmes that deliver improved market success. Frost & Sullivans strengths lie in combining strategic understanding with market expertise and applying these with absolute commitment to its clients growth.

1 QUANTITATIVE ANALYSIS OF GLOBAL BIOPHARMACEUTICAL MANUFACTURING

Overview
- Overview
Research Scope and Methodology
- Research Scope and Methodology
Introduction and Background
- Introduction to the Biopharmaceutical Industry
- What are Biopharmaceuticals?
- Why Biopharmaceuticals
- Current Technologies and Applications
- Market Segmentations
Market Dynamics
- Industry Challenges
- Major Challenges and Strategies
- Key Market Trends
- Key Technology Trends
- Key Market Drivers
- Key Market Restraints
Industry Outlook
- Industry Review
Capacity Forecasts - Supply
- Key Market Engineering Measurements
- Forecast Assumptions
- Total Manufacturing Capacity Forecasts
- Total Manufacturing Capacity Analysis
- CMO vs Captive Manufacturing Capacity Forecasts
Captive Manufacturing Capacity
- Key Market Engineering Measurements
- Total Captive Manufacturing Capacity Forecasts
- Captive Manufacturing Capacities Analysis
Contract Manufacturing Capacity
- Key Market Engineering Measurements
- Total Contract Manufacturing Capacity Forecasts
- Contract Manufacturing Capacities Analysis
Demand Forecasts for Manufacturing Capacity
- Key Market Drivers for Capacity-Demand
- Key Issues for Capacity Demand
- Key Market Engineering Measurements
- Total Manufacturing Capacity Demand Forecasts
- Manufacturing Capacities Demand Analysis
- Capacity Demand in North America and Europe
Supply-Demand Balance in Biopharmaceutical Manufacturing
- Capacity Supply and Utilisation Curves
- Industry Capacity Utilisation (2003-2011)
- Industry Capacity Utilisation Analysis
- Implications of Over Capacity
Strategic Analysis and Recommendations
- Biopharmaceutical Industry is at Growth Phase
- Strategic Anticipation
- "I Think It Might Happen"
- Potential Threats to Biopharmaceuticals
- Market Potential in the Biopharmaceutical Industry
- Current and Future Status of the Industry
- Three Levels of Key Strategies
- Pricing of Biopharmaceuticals
- What can be Expected in the Future?
- Meeting the Challenge
Frost & Sullivan Awards
- Frost & Sullivan Awards
- Market Leadership Award of the Year
- Customer Value Leadership Award of the Year
- Market penetration Leadership Award of the Year
- Competitive Strategy Leadership Award of the Year
- Growth Strategy Leadership Award of the Year
Key Industry Participants
- Industry Participants
Decision Support Databases
- Decision Support Databases
About Frost & Sullivan
- Our Team
- Consulting Capabilities